share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K：外國發行人報告
SEC announcement ·  03/13 21:08
牛牛AI助理已提取核心訊息
SciSparc Ltd., a foreign private issuer, reported on March 12, 2024, that its collaborative venture MitoCareX Bio Ltd. has made significant progress in the development of cancer therapeutics. MitoCareX, working with Dr. Alon Silberman, has virtually screened millions of small molecules using a computational drug discovery platform, identifying several with potential anti-cancer properties. These findings were validated through in-vitro screening systems targeting the mitochondrial SLC25 protein family. Furthermore, MitoCareX is advancing towards the creation of a predictive AI model to enhance the efficiency of navigating chemical spaces and discovering novel anti-cancer scaffolds. The report includes forward-looking statements and is incorporated by reference into the company's registration statements filed with the SEC. SciSparc's CEO and CFO, Oz Adler, signed the report on March 13, 2024.
SciSparc Ltd., a foreign private issuer, reported on March 12, 2024, that its collaborative venture MitoCareX Bio Ltd. has made significant progress in the development of cancer therapeutics. MitoCareX, working with Dr. Alon Silberman, has virtually screened millions of small molecules using a computational drug discovery platform, identifying several with potential anti-cancer properties. These findings were validated through in-vitro screening systems targeting the mitochondrial SLC25 protein family. Furthermore, MitoCareX is advancing towards the creation of a predictive AI model to enhance the efficiency of navigating chemical spaces and discovering novel anti-cancer scaffolds. The report includes forward-looking statements and is incorporated by reference into the company's registration statements filed with the SEC. SciSparc's CEO and CFO, Oz Adler, signed the report on March 13, 2024.
外國私人發行人ScisPARC Ltd. 於2024年3月12日報告稱，其合作企業MitoCarex Bio Ltd.在癌症療法的開發方面取得了重大進展。MitoCarex與阿隆·西爾伯曼博士合作，使用計算藥物發現平台虛擬篩選了數百萬個小分子，確定了幾種具有潛在抗癌特性的小分子。這些發現通過針對線粒體 SLC25 蛋白家族的體外篩查系統得到驗證。此外，MitoCarex正在努力創建預測性人工智能模型，以提高在化學空間中導航和發現新型抗癌支架的效率。該報告包括前瞻性陳述，並以引用方式納入公司向美國證券交易委員會提交的註冊聲明中。ScisPARC的首席執行官兼首席財務官奧茲·阿德勒於2024年3月13日簽署了該報告。
外國私人發行人ScisPARC Ltd. 於2024年3月12日報告稱，其合作企業MitoCarex Bio Ltd.在癌症療法的開發方面取得了重大進展。MitoCarex與阿隆·西爾伯曼博士合作，使用計算藥物發現平台虛擬篩選了數百萬個小分子，確定了幾種具有潛在抗癌特性的小分子。這些發現通過針對線粒體 SLC25 蛋白家族的體外篩查系統得到驗證。此外，MitoCarex正在努力創建預測性人工智能模型，以提高在化學空間中導航和發現新型抗癌支架的效率。該報告包括前瞻性陳述，並以引用方式納入公司向美國證券交易委員會提交的註冊聲明中。ScisPARC的首席執行官兼首席財務官奧茲·阿德勒於2024年3月13日簽署了該報告。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。